These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21561667)

  • 1. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
    Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
    Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
    Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
    Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
    Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
    Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
    Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
    Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
    Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
    Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
    Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
    Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
    Irie M; Takeuchi Y; Ohtake Y; Suzuki H; Nagata N; Miyoshi T; Kagawa Y; Yamagami T
    J Vet Med Sci; 2015 Nov; 77(11):1535-9. PubMed ID: 26074249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
    Mital A; Piskorz A; Lewandowski K; Wasąg B; Limon J; Hellmann A
    Eur J Haematol; 2011 Jun; 86(6):531-5. PubMed ID: 21362052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
    Cairoli R; Beghini A; Morello E; Grillo G; Montillo M; Larizza L; Morra E
    Leuk Res; 2005 Apr; 29(4):397-400. PubMed ID: 15725473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
    Nakano Y; Kobayashi M; Bonkobara M; Takanosu M
    Vet Immunol Immunopathol; 2017 Jun; 188():84-88. PubMed ID: 28615132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.